MONROVIA, Calif. , May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Mark Lotz ,
MONROVIA, Calif. , Nov. 30, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option to
MONROVIA, Calif. , Feb. 23, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, up to 5,500,000 shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day
MONROVIA, Calif. , March 19, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option
MONROVIA, Calif. , March 2, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the completion of an underwritten public offering of 8,625,000 shares of its common stock, including 1,125,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters
MONROVIA, Calif. , Dec. 6, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced the completion of an underwritten public offering of 5,272,750 shares of its common stock, including 687,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to
MONROVIA, Calif. , Dec. 6, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial public offering price of $5.50 per share, which includes the exercise in full by the underwriters of their
MONROVIA, Calif. , May 11, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that data from the Phase 1b/2a
MONROVIA, Calif., October 1, 2013—Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor's class of therapeutic antibodies
MONROVIA, Calif. , Sept. 24, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that its partner CSL Limited has
